Rates and Durability of Response to Salvage Radiation Therapy Among Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma

被引：2
|
作者：
Tseng, Y. D. [1 ]
Chen, Y. [2 ]
Catalano, P. [2 ]
Mauch, P. M. [3 ]
Ng, A. [3 ]
机构：
[1] Harvard Radiat Oncol Program, Boston, MA USA
[2] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2013年 / 87卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2013.06.156
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S60 / S60
页数：1
相关论文
共 50 条
  • [21] Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
    Keating, Gillian M.
    DRUGS, 2016, 76 (16) : 1579 - 1586
  • [22] Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma
    Blum, Kristie A.
    Hamadani, Mehdi
    Phillips, Gary S.
    Lozanski, Gerard
    Johnson, Amy J.
    Lucas, David M.
    Smith, Lisa L.
    Baiocchi, Robert
    Lin, Thomas S.
    Porcu, Pierluigi
    Devine, Steven M.
    Byrd, John C.
    LEUKEMIA & LYMPHOMA, 2009, 50 (03) : 349 - 356
  • [23] High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma
    Vijay, Archana
    Duan, Qiuli
    Henning, Jan-Willem
    Duggan, Peter
    Daly, Andrew
    Shafey, Mona
    Bahlis, Nizar J.
    Stewart, Douglas Allan
    LEUKEMIA & LYMPHOMA, 2013, 54 (12) : 2620 - 2626
  • [24] Salvage therapy with mitoxantrone, etoposide, bleomycin and dexamethasone for refractory or relapsed aggressive non-Hodgkin's lymphoma patients with a poor performance status or comorbidity
    Lin, Xuede
    Shi, Xi
    Zeng, Wucha
    Zheng, Min
    Huang, Liming
    ONCOLOGY LETTERS, 2014, 8 (05) : 2012 - 2016
  • [25] SALVAGE THERAPY WITH PROMACE IN RELAPSED NON-HODGKIN MALIGNANT-LYMPHOMA
    NIELSEN, H
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1991, 46 (02) : 123 - 124
  • [26] Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma
    Haq, R
    Sawka, CA
    Franssen, E
    Berinstein, NL
    LEUKEMIA & LYMPHOMA, 1999, 35 (5-6) : 527 - 536
  • [27] International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma
    Czuczman, M. S.
    Reeder, C. B.
    Polikoff, J.
    Chowhan, N. M.
    Esseessee, I.
    Greenberg, R.
    Ervin-Haynes, A.
    Pietronigro, D.
    Zeldis, J. B.
    Witzig, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
    Roschewski, Mark
    Izumi, Raquel
    Hamdy, Ahmed
    Patel, Manish R.
    Arkenau, Hendrik-Tobias
    de Vos, Sven
    Reagan, Patrick M.
    Zinzani, Pier Luigi
    Davies, Andrew
    Pagel, John M.
    Vose, Julie M.
    Bitman, Bojena
    Brock, Graham
    Clark, Edwin
    Frigault, Melanie M.
    Ware, Joseph
    Yang, Buyue
    Wilson, Wyndham
    Staudt, Louis
    Flinn, Ian W.
    BLOOD, 2019, 134
  • [29] Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
    Younes, A
    Preti, HA
    Hagemeister, FB
    McLaughlin, P
    Romaguera, JE
    Rodriguez, MA
    Samuels, BI
    Palmer, JL
    Cabanillas, F
    ANNALS OF ONCOLOGY, 2001, 12 (07) : 923 - 927
  • [30] Response to re-treatment with rituximab plus salvage-chemotherapy in refractory or relapsed aggressive Non-Hodgkin's lymphoma.
    Borgerding, Andrea
    Hasenkamp, Justin
    Chapuy, Bjoern
    Truemper, Lorenz
    Wulf, Gerald
    Glass, Bertram
    BLOOD, 2006, 108 (11) : 262B - 263B
12345